Physician profile
Colyn G Wright
NPI 1477207280
$7,057.28
in general payments reported to CMS, 2019-2025
34 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.66 · 2023: $2,411 · 2024: $2,192 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,969.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,675.21 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $597.40 | 2023-2025 | Entyvio, Aralast, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $583.58 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $442.96 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $433.25 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $354.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $349.21 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $343.58 | 2022-2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $340.90 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $212.78 | 2023-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $181.56 | 2023-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $158.92 | 2024-2025 | Omvoh, Zepbound |
| Ironwood Pharmaceuticals, INC | $151.48 | 2023-2024 | Linzess |
| Evoke Pharma, INC. | $136.71 | 2024-2025 | |
| Gilead Sciences, INC. | $133.32 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.94 | 2023-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $107.69 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
| Nestle Healthcare Nutrition INC. | $79.31 | 2023 | |
| Axsome Therapeutics, INC. | $77.07 | 2023 | Sunosi |
| Ferring Pharmaceuticals INC. | $66.86 | 2023-2024 | Rebyota |
| Verona Pharma, INC. | $61.76 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $57.42 | 2023 | Opsumit, Uptravi |
| Aimmune Therapeutics, INC. | $57.17 | 2024-2025 | Zenpep |
| Vanda Pharmaceuticals INC. | $55.02 | 2023 | Hetlioz |
| Braintree Laboratories, INC. | $49.17 | 2024-2025 | Suflave |
| Jazz Pharmaceuticals INC. | $46.14 | 2023 | |
| Intercept Pharmaceuticals, INC. | $43.96 | 2023-2025 | Ocaliva |
| Mylan Specialty L.P. | $41.88 | 2023 | Yupelri |
| Celgene Corporation | $23.27 | 2023 | Zeposia |
| Grifols USA, LLC | $16.91 | 2025 | Prolastin-C Liquid |
| Pfizer INC. | $15.80 | 2025 | |
| Paratek Pharmaceuticals, INC. | $14.54 | 2023 | Nuzyra |
| Novo Nordisk INC | $14.49 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $13.72 | 2023 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colyn Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.